Belzutifan Plus Pembrolizumab Cuts Kidney Cancer Recurrence by 28% After Surgery in Phase 3 Trial
In 1,841 patients with high-risk clear cell renal cell carcinoma, adding belzutifan to post-surgical pembrolizumab reduced recurrence by 28% compared to pembrolizumab plus placebo in the phase 3 LITESPARK-022 trial, though overall survival data are still too early to analyze.